+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Meningitis Diagnostic Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 120 Pages
  • June 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4896222
The meningitis diagnostics testing market is expected to grow at a registered CAGR of 3.8% during the forecast period, 2022-2027.

The COVID-19 pandemic has resulted in a decrease in vaccine uptake and coverage owing to the fear of contracting the virus among the population and several restrictions imposed on social distancing. Individuals have misinterpreted COVID-19's "stay at home" advice to mean that they should not take their children to routine immunization appointments or that they are afraid of exposing their children to the virus. Others had trouble getting routine immunizations due to unavailability of primary care or self-isolation due to COVID-19. For instance, according to the study titled "Meningitis during COVID -19 pandemic in the Democratic Republic of Congo: A call for concern" published in the Clinical Epidemiology and Global Health in February 2022, the meningitis outbreak in the Democratic Republic of Congo (DRC), which emerged amid the coronavirus disease 2019 pandemic, added to the strain on healthcare systems that were already overwhelmed with detecting, preventing, and treating the current coronavirus disease. In the DRC, a recent meningitis outbreak resulted in a high case fatality rate of 50%. Such instances are likely to boost the market's growth throughout the pandemic phase.

The global meningitis diagnosis market is being driven by rising meningitis prevalence and increased efforts to combat the disease, such as efforts to reduce the disease's incidence and better control the disease. Growing demand for point-of-care diagnostic services as well as increasing R&D investments for effective diagnosis and treatment is expected to propel the global meningitis diagnosis market over the forecast period.

For instance, according to the study titled "A systematic literature review on the prevalence and etiology of meningitis among critically ill and hospitalized patients in India" published in the Infectious Diseases in December 2021, in the pediatric population (0-14 years), the prevalence of confirmed bacterial meningitis ranged from 0.5 percent to 61.8 percent. In one study, meningitis was found to be prevalent in patients of all ages (0-75 years), with a prevalence ranging from 8.68 percent to 78.85 percent. Cryptococcal meningitis was most common in HIV/AIDS patients, with a prevalence ranging from 2.09 percent to 53.1 percent. Thus, the increasing prevalence of meningitis is anticipated to boost the market over the forecast period. Furthermore, according to the World Health Organization report in May 2020, despite significant progress in recent decades, meningitis remains a highly feared disease with a high case fatality rate and a proclivity for causing epidemics that pose a significant threat to health systems, economies, and society. In 2019, an estimated 250,000 people died from meningitis, with one in every five people affected suffering long-term consequences.

Additionally, increased participation of the government to control the outbreaks of meningitis and a rise in the demand for immediate diagnosis systems, are expected to contribute to the growth of the global market. World Health Organization, with global partners and experts involved in meningitis prevention and control, led the development of a global road map that sets forth a vision and roadmap to defeat meningitis by 2030, involving hundreds of experts, Member States representatives, partners, Civil Society Organization as well as private sector representatives, through multidisciplinary, iterative, and comprehensive consultations. Such initiatives will help increase the awareness regarding early diagnosis of meningitis, thereby boosting the market growth.

The study titled "Characteristics and biomarkers of patients with central nervous system infection admitted to a referral hospital in Northern Vietnam" published in May 2021 suggests that raised cerebrospinal fluid adenosine deaminase levels (10 IU/L) were strongly associated with bacterial and tubercular meningitis which is a central nervous system infection. Thus, this biomarker might help diagnose tubercular meningitis. Such increasing usage of biomarkers along with companion diagnostic tests may have a positive impact on the market growth in the near future.

However, a complex regulatory framework and lack of awareness might hamper the market growth over the forecast period.

Key Market Trends

PCR Assay Tests Segment is Expected to Hold the Largest Market Share in the Meningitis Diagnostic Testing Market

The PCR assays tests segment is anticipated to hold the largest market share in the meningitis diagnostic testing market. The highest market revenue is due to its highly precise and accurate test results in a short time in comparison to conventional tests, with the highest sensitivity rate.

According to the study titled "Outcomes of implementation of the FilmArray meningoencephalitis panel in a tertiary hospital between 2017 and 2020" published in the PLOS One Journal in March 2022, the FilmArray ME panel's implementation was relatively simple. A change in workflow processes enabled the researcher to streamline CSF diagnostics and safely remove Gram staining from samples tested by this molecular assay. In addition to this improvement, the rapid turnaround time for results had a positive clinical impact on patient care. Such technological advancement in the products is likely to boost the PCR assay tests segment's growth throughout the forecast period.

Moreover, product launches by the key market players to extend the product portfolio are expected to impel the segment's growth. For instance, in January 2022, QIAGEN N.V. reported the enhancements in the commercialization of its QIAstat-Dx syndromic testing solution, which enables laboratories and hospitals worldwide to test patients for multiple pathogens from one sample, with new tests and the launch of a higher-throughput version that includes a new level of walk-away efficiency through the new QIAstat-Dx Smart Drawer. New tests for QIAstat-Dx syndromic solution can distinguish between gastrointestinal pathogens and between meningitis and encephalitis infections.

Thus, all the aforementioned factors are anticipated to boost the market segment over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the overall meningitis diagnostic testing market throughout the forecast period. The high adoption rate of advanced diagnostic devices, the increased number of diagnostic centers, and easy availability of diagnostic test kits are the factors estimated to fuel the market in North America.

Within the region, the United States holds the largest market share due to the increased patient pool and the presence of key market players in the country. For instance, the Centers for Disease Control and Prevention issued an outbreak notice in April 2021, stating that Florida was experiencing a significant, ongoing outbreak of meningococcal disease, particularly among gay and bisexual men, including HIV-positive men. The outbreak in Florida occurred at the same time when the Centers for Disease Control and Prevention (CDC) reported a significant increase in sexually transmitted diseases (STDs), such as gonorrhea, syphilis, and congenital syphilis. According to the CDC's National STD Surveillance Report, reported cases of gonorrhea climbed by 10% and syphilis cases increased by 7% in 2020. Thus, such a high prevalence of infectious diseases is projected to drive the global meningitis diagnostic testing market sales over the forecast period.

Additionally, according to the Center for Disease Control and Prevention Updates in June 2021, 2019, approximately 375 cases of meningococcal disease were reported in the United States (an incidence rate of 0.11 cases per 100,000 persons).

Moreover, in the United States, the Meningitis Foundation of America (MFA), a non-profit organization, provides information and support to individuals who have had personal experiences with meningitis. This foundation is also involved in creating awareness in the public and the medical community about the initial symptoms of meningitis. Thus, owing to all the above-mentioned factors, the meningitis diagnosis testing market is expected to witness growth over the forecast period.

Competitive Landscape

The meningitis diagnostic testing market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some prominent players are vigorously making acquisitions with the other companies to consolidate their market positions across the globe and while others are launching new products. Some of the companies which are currently dominating the market are Seegene Inc., Siemens Healthineers, IMMY, Thermo Fisher Scientific Inc, and BioFire Diagnostics LLC (BioMérieux).

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the Global Prevalence of Meningitis
4.2.2 Increased Demand for Advanced Diagnostics for Sensitive Reports and Accurate Diagnosis
4.3 Market Restraints
4.3.1 Complex Regulatory Framework by Authorities
4.3.2 Lack of Awareness Regarding of Diagnosis and Availability of Diagnostic Laboratories In Developing Countries
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Test Type
5.1.1 Latex Agglutination Tests
5.1.2 Lateral Flow Assay
5.1.3 PCR Assay
5.1.4 ELISA Tests
5.1.5 Culture Test
5.1.6 Others
5.2 By End User
5.2.1 Hospital
5.2.2 Diagnostic Center
5.2.3 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Seegene Inc.
6.1.2 Siemens Healthineers AG
6.1.3 IMMY
6.1.4 Thermo Fisher Scientific Inc.
6.1.5 BioFire Diagnostics LLC (Biomerieux)
6.1.6 Bio-Rad Laboratories Inc.
6.1.7 ELITechGroup
6.1.8 Abbott Laboratories
6.1.9 Becton, Dickinson and Company
6.1.10 Luminex Corporation

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Seegene Inc.
  • Siemens Healthineers AG
  • IMMY
  • Thermo Fisher Scientific Inc.
  • BioFire Diagnostics LLC (Biomerieux)
  • Bio-Rad Laboratories Inc.
  • ELITechGroup
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Luminex Corporation